MUC5AC and neoplasm: Thus, for the first time, this protocol breaks the mucin barrier in PMP and allows access to the protein fraction in this rare tumour type, opening new perspectives for other more common mucinous tumours, such as mucinous colorectal cancer (CRC), which accounts for 10%—20% of CRC patients [27].